These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 26886788)
1. Clinical significance of serum claudin-1 levels in melanoma patients. Tas F; Bilgin E; Erturk K; Duranyildiz D Melanoma Res; 2016 Aug; 26(4):377-81. PubMed ID: 26886788 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum caveolin-1 levels in melanoma patients. Tas F; Karabulut S; Tilgen Yasasever C; Duranyildiz D Int J Dermatol; 2016 May; 55(5):558-62. PubMed ID: 26084616 [TBL] [Abstract][Full Text] [Related]
3. Clinical significance of serum fibronectin and vitronectin levels in melanoma patients. Tas F; Karabulut S; Bilgin E; Tastekin D; Duranyildiz D Melanoma Res; 2014 Oct; 24(5):475-9. PubMed ID: 24999757 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum M30 and M65 levels in melanoma. Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330 [TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Circulating Serum Cellular Heat Shock Protein 90 (HSP90) Level in Patients with Cutaneous Malignant Melanoma. Tas F; Bilgin E; Erturk K; Duranyildiz D Asian Pac J Cancer Prev; 2017 Mar; 18(3):599-601. PubMed ID: 28440609 [TBL] [Abstract][Full Text] [Related]
6. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447 [TBL] [Abstract][Full Text] [Related]
7. Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. Hügel R; Muendlein A; Volbeding L; Drexel H; Richtig E; Wehkamp U; Painsi C; Lange-Asschenfeldt B; Hauschild A; Egberts F Melanoma Res; 2016 Aug; 26(4):354-60. PubMed ID: 27206057 [TBL] [Abstract][Full Text] [Related]
8. Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Vihinen P; Kallioinen M; Vuoristo MS; Ivaska J; Syrjänen KJ; Hahka-Kemppinen M; Kellokumpu-Lehtinen PL; Pyrhönen SO Clin Exp Metastasis; 2007; 24(7):567-74. PubMed ID: 17762972 [TBL] [Abstract][Full Text] [Related]
9. Serum transforming growth factor-beta 1 (TGF-β1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma. Tas F; Karabulut S; Yasasever CT; Duranyildiz D Tumour Biol; 2014 Jul; 35(7):7233-7. PubMed ID: 24771267 [TBL] [Abstract][Full Text] [Related]
10. Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer. Tas F; Yasasever CT; Karabulut S; Tastekin D; Duranyildiz D Tumour Biol; 2015 Mar; 36(3):2097-103. PubMed ID: 25391430 [TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723 [TBL] [Abstract][Full Text] [Related]
12. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients. Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379 [TBL] [Abstract][Full Text] [Related]
13. Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma. Karabulut M; Gunaldi M; Alis H; Afsar CU; Karabulut S; Serilmez M; Akarsu C; Seyit H; Aykan NF Clin Transl Oncol; 2016 Feb; 18(2):160-71. PubMed ID: 26184725 [TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic significance of coagulation assays in melanoma. Tas F; Ciftci R; Kilic L; Bilgin E; Keskin S; Sen F; Yildiz I; Yasasever V Melanoma Res; 2012 Oct; 22(5):368-75. PubMed ID: 22889867 [TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L; Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041 [TBL] [Abstract][Full Text] [Related]
16. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels. Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J Oncology; 2003; 64(4):374-9. PubMed ID: 12759535 [TBL] [Abstract][Full Text] [Related]
17. Serum S100--a marker for disease monitoring in metastatic melanoma. Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834 [TBL] [Abstract][Full Text] [Related]
18. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789 [TBL] [Abstract][Full Text] [Related]
19. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein. Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Soubrane C; Rixe O; Meric JB; Khayat D; Mouawad R Melanoma Res; 2005 Jun; 15(3):199-204. PubMed ID: 15917702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]